Contact Us
Drug Search Results
More Filters [+]

BMS-817378

Alternative Names: bms-817378, bms817378, bms 817378, bms-777607, bms 777607, bms777607
Latest Update: 2023-09-26
Latest Update Note: PubMed Publication

Product Description

For Advanced Solid Tumors (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00792558)

Mechanisms of Action: C-Met Inhibitor,AXL Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BMS-817378

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Prostate Cancer|Papillary Carcinoma|Squamous Cell Carcinoma|Head and Neck Cancer|Esophageal Cancer|Gastrointestinal Cancer|Renal Cell Carcinoma

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ASLAN002-001

P1

Completed

Oncology Solid Tumor Unspecified

2016-12-01

CA195-001

P1

Withdrawn

Oncology Solid Tumor Unspecified

2010-11-01

CA192-002

P2

Completed

Papillary Carcinoma|Squamous Cell Carcinoma|Esophageal Cancer|Head and Neck Cancer|Gastrointestinal Cancer|Prostate Cancer|Renal Cell Carcinoma

2009-03-01

Recent News Events

Date

Type

Title

09/26/2023

PubMed

 Efferocytosis Nanoinhibitors to Promote Secondary Necrosis and Potentiate the Immunogenicity of Conventional Cancer Therapies for Improved Therapeutic Benefits.

09/05/2023

PubMed

 Design, synthesis and biological evaluation of 4-(4-aminophenoxy)picolinamide derivatives as potential antitumor agents.

05/01/2023

PubMed

 RON-augmented cholesterol biosynthesis in breast cancer metastatic progression and recurrence.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions